Abbott Laboratories · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← ABT

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q1	2026-03-31	11.16	+7.8%	56.2%	1.35	1.08	9.6%	0.92	0.61	0.18	1.10
FY2025 Q4	2025-12-31	11.46	+4.4%	57.0%	2.25	1.78	15.5%	2.63	1.01	0.30	1.03
FY2025 Q3	2025-09-30	11.37	+6.9%	55.4%	2.06	1.64	14.5%	2.29	0.94	0.31	1.03
FY2025 Q2	2025-06-30	11.14	+7.4%	56.4%	2.05	1.78	16.0%	1.55	1.01	0.01	1.03
FY2025 Q1	2025-03-31	10.36	+4.0%	56.9%	1.69	1.33	12.8%	0.93	0.76	0.28	1.03
FY2024 Q4	2024-12-31	10.97	+7.2%	55.0%	1.91	9.23	84.1%	2.15	5.26	0.32	0.96
FY2024 Q3	2024-09-30	10.64	+4.9%	55.8%	1.86	1.65	15.5%	2.15	0.94	0.75	0.96
FY2024 Q2	2024-06-30	10.38	+4.0%	55.6%	1.67	1.30	12.5%	1.43	0.74	0.00	0.96
FY2024 Q1	2024-03-31	9.96	+2.2%	55.2%	1.39	1.23	12.3%	0.63	0.70	0.23	0.96
FY2023 Q4	2023-12-31	10.24	+1.5%	55.5%	1.78	1.59	15.6%	2.28	0.91	0.26	0.89
FY2023 Q3	2023-09-30	10.14	−2.6%	54.6%	1.65	1.44	14.2%	1.32	0.82	0.00	0.89
FY2023 Q2	2023-06-30	9.98	−11.4%	55.1%	1.54	1.38	13.8%	0.70	0.78	0.43	0.89
FY2023 Q1	2023-03-31	9.75	—	55.6%	1.51	1.32	13.5%	0.76	0.75	0.54	0.89
FY2022 Q4	2022-12-31	10.09	—	54.5%	1.30	1.03	10.2%	1.72	0.59	0.69	0.82
FY2022 Q3	2022-09-30	10.41	—	55.5%	1.77	1.44	13.8%	2.31	0.81	0.80	0.83
FY2022 Q2	2022-06-30	11.26	—	56.2%	2.38	2.02	17.9%	2.03	1.14	0.01	0.83

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.